{"id":"ad-227a","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL5747425","moleculeType":null,"molecularWeight":"550.98"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by activating the serotonin receptor, which can help to reduce symptoms of depression and anxiety. However, the exact mechanism of action is not fully understood and more research is needed to confirm its effects.","oneSentence":"AD-227A is a small molecule drug that targets the serotonin receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:34.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT06884085","phase":"PHASE1","title":"A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2025-07-12","conditions":"Primary Hypertension","enrollment":70},{"nctId":"NCT06441630","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B","status":"RECRUITING","sponsor":"Addpharma Inc.","startDate":"2024-07-31","conditions":"Essential Hypertension","enrollment":251}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AD-227A","genericName":"AD-227A","companyName":"Addpharma Inc.","companyId":"addpharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AD-227A is a small molecule drug that targets the serotonin receptor. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}